ScholarLens Back to search
2024•Clinical and Experimental DermatologyRequires access

How useful is chest X-ray in addition to routine QuantiFERON® in the detection of latent tuberculosis prior to biologics?

Niamh Kearney, Fawad Aslam, Grace Boyd, Natasha Boylan, Emma Laverty, Rosie O’Hare, Victoria Campbell, Susannah Hoey, Donal O’Kane

Open publisher page 4 citations

Abstract

Screening with QuantiFERON®/interferon-γ release assay (IGRA) and chest X-ray (CXR) for latent tuberculosis (TB) infection is recommended by the British Association of Dermatologists prior to commencing some biologics. QuantiFERON is highly sensitive, while CXR is poorly sensitive and poorly specific. In our cohort of 995 patients, 2.3% had a positive IGRA and 8.7% had any abnormality on CXR, with only 0.8% suggestive of TB. Patients were just as likely to have an abnormal CXR if they had a positive or negative IGRA (P = 0.93). We suggest that routine screening with IGRA alone is sufficient in the dermatology population, particularly in the setting of a low TB incidence country such as the UK.

About this research paper

What this paper is about

Screening with QuantiFERON®/interferon-γ release assay (IGRA) and chest X-ray (CXR) for latent tuberculosis (TB) infection is recommended by the British Association of Dermatologists prior to commencing some biologics. QuantiFERON is highly sensitive, while CXR is poorly sensitive and poorly specific. In our cohort of 995 patients, 2.3% had a positive IGRA and 8.7% had any abnormality on CXR, with only 0.8% suggestive of TB. Patients were just as likely to have an abnormal CXR if they had a positive or negative IGRA (P = 0.93). We suggest that routine screening with IGRA alone is sufficient in the dermatology population, particularly in the setting of a low TB incidence country such as the UK.

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Screening with QuantiFERON®/interferon-γ release assay (IGRA) and chest X-ray (CXR) for latent tuberculosis (TB) infection is recommended by the British Association of Dermatologists prior to commencing some biologics. QuantiFERON is highly sensitive, while CXR is poorly sensitive and poorly specific. In our cohort of 995 patients, 2.3% had a positive IGRA and 8.7% had any abnormality on CXR, with only 0.8% suggestive of TB. Patients were just as likely to have an abnormal CXR if they had a positive or negative IGRA (P = 0.93). We suggest that routine screening with IGRA alone is sufficient in the dermatology population, particularly in the setting of a low TB incidence country such as the UK.

Key concepts: Medicine, QuantiFERON, Latent tuberculosis, Tuberculosis, Interferon gamma release assay, Incidence (geometry), Mycobacterium tuberculosis, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
How useful is chest X-ray in addition to routine QuantiFERON® in the detection of latent tuberculosis prior to biologics? — Research Paper | ScholarLens